The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Update: Infliximab Biosimilar Garners Support & Fibromyalgia Drug Receives Fast Track

FDA Update: Infliximab Biosimilar Garners Support & Fibromyalgia Drug Receives Fast Track

February 17, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Infliximab Biosimilar Garners FDA Support
Announced on Feb. 5 ahead of the U.S. Food and Drug Administration (FDA) Arthritis Advisory Committee meeting on Feb. 9, FDA reviewers concluded that Celltrion’s biosimilar CT-P13 is “highly similar” to Johnson & Johnson’s infliximab (Remicade).1,2 Staff stated that clinical development program results and Celltrion’s data support that that there are “no clinically meaningful differences” between CT-P13 and infliximab with regard to potency, purity and safety for treating rheumatoid arthritis and ankylosing spondylitis. These were the two indications that were studied.

You Might Also Like
  • Infliximab Biosimilar Receives FDA Approval
  • Rheumatology Drug Updates: Infliximab Biosimilar Gets FDA Approval & More
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
Also By This Author
  • FDA Grants Octapharma 7-Year Market Exclusivity for Octagam 10%

The FDA staff assumes that the biosimilar CT-P13 would also be safe for infliximab’s other approved indications, including Crohn’s disease and ulcerative colitis. The investigation by FDA staff noted that only minor differences in clinically inactive components were noted between the two products.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Fibromyalgia Treatment Receives FDA Fast Track Designation
The FDA fast track designation is given to a product that addresses an unmet medical need in a serious condition. In January, the FDA fast tracked the development of IMC-1 for treating fibromyalgia.3 IMC-1 suppresses the chronic tissue-resident herpes virus, which may have a role in causing or continuing fibromyalgia symptoms.

Previously, IMC-1 completed a randomized, double-blinded, placebo-controlled Phase 2 study, known as PRID-201. This study showed that IMC-1 holds promise for treating pain and other fibromyalgia symptoms. The product is a fixed-dose combination of famciclovir and celecoxib, the former of which possesses anti-viral activity. The formulation and dosing are proprietary to the manufacturer, Innovative Med Concepts.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

IMC-1 is expected to begin Phase 3 clinical trials in 2017.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Bloomberg staff. FDA staff express support for Celltrion’s biosimilar version of Johnson & Johnson’s Remicade. FristWord Pharma. 2016 Feb 5.
  2. U.S. Food and Drug Administration. FDA Briefing Document Arthritis Advisory Committee Meeting: BLA 125544 AAC Brief CT-P13, a proposed biosimilar to Remicade. 2016 Feb 8.
  3. Innovative Med Concepts Inc. News release: Innovative Med Concepts announces receipt of FDA fast track designation for IMC-1, a novel treatment for fibromyalgia. 2016 Jan 28.

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: drug development, FDA, Fibromyalgia, Food and Drug Administration, infliximab

You Might Also Like:
  • Infliximab Biosimilar Receives FDA Approval
  • Rheumatology Drug Updates: Infliximab Biosimilar Gets FDA Approval & More
  • FDA Approves Biosimilar to J&J’s Remicade for Multiple Diseases
  • Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.